A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS resultsDavid Cunningham, Eric Van Cutsem, Rlc Wong et al.|Journal of Clinical Oncology|2008Cited by 29
Risk Factors and Clinical Outcomes of Head and Neck Cancer in Inflammatory Bowel Disease: A Nationwide Cohort StudyLoes H.C. Nissen, Julie M. Janssen, Lauranne Derikx et al.|Inflammatory Bowel Diseases|2018Cited by 14
DOP79 Biomarkers for IBD using OLINK Proteomics inflammation panel: Preliminary results from the COLLIBRI consortiumPadhmanand Sudhakar, Jonas Halfvarson, Mark S. Silverberg et al.|Journal of Crohn s and Colitis|2022Cited by 4
Infliximab and Ustekinumab Clearance Better Predict Endoscopic Outcomes Than Trough Concentrations in Crohn’s DiseaseZhigang Wang, Erwin Dreesen, Yannick Hoffert et al.|Clinical Gastroenterology and Hepatology|2025Cited by 3